Download PDF
Semin Respir Crit Care Med 2016; 37(05): 727-735
DOI: 10.1055/s-0036-1592112
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Stage III Non-small Cell Lung Cancer

Valerie W. Rusch
1   Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
› Author Affiliations
Further Information

Publication History

Publication Date:
12 October 2016 (online)

    Permissions and Reprints

Abstract

More than 20% of non-small cell lung cancers (NSCLCs) are classified as stage III disease at diagnosis because they are locoregionally advanced tumors. Local therapy alone (surgery or radiation) leads to poor overall survival in stage III NSCLC because most of the patients with NSCLC die of distant metastases. Therefore, during the past 20 years, studies have focused on developing effective chemotherapy regimens that can be combined with local therapies (surgery and/or radiation). The role of surgery has been extensively evaluated and the selection criteria for resection defined.

Keywords

lung cancer - multimodality therapy - IIIA (N2)
 

  • References

  • 1 Rami-Porta R, Bolejack V, Crowley J , et al; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 2015; 10 (7) 990-1003
    CrossrefPubMedGoogle Scholar
  • 2 Asamura H, Chansky K, Crowley J , et al. Proposals for the revision of the N descriptors in the forthcoming eighth edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2015; 10 (12) 1675-1684
    CrossrefPubMedGoogle Scholar
  • 3 Eberhardt WEE, Mitchell A, Crowley J , et al; International Association for Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Board Members, and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2015; 10 (11) 1515-1522
    CrossrefPubMedGoogle Scholar
  • 4 Goldstraw P, Chansky K, Crowley J , et al; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 2016; 11 (1) 39-51
    CrossrefPubMedGoogle Scholar
  • 5 Martini N, Flehinger BJ. The role of surgery in N2 lung cancer. Surg Clin North Am 1987; 67 (5) 1037-1049
    PubMedGoogle Scholar
  • 6 Rocco G, Nason K, Brunelli A, Varela G, Waddell T, Jones DR. Management of stage IIIA (N2) non-small cell lung cancer: a transatlantic perspective. J Thorac Cardiovasc Surg 2016; 151 (5) 1235-1238
    CrossrefPubMedGoogle Scholar
  • 7 Silvestri GA, Gonzalez AV, Jantz MA , et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143 (5) e211S-e250S
    CrossrefPubMedGoogle Scholar
  • 8 De Leyn P, Dooms C, Kuzdzal J , et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg 2014; 45 (5) 787-798
    CrossrefPubMedGoogle Scholar
  • 9 Yasufuku K, Pierre A, Darling G , et al. A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg 2011; 142 (6) 1393-400.e1
    CrossrefPubMedGoogle Scholar
  • 10 Trisolini R, Cancellieri A, Tinelli C , et al. Randomized trial of endobronchial ultrasound-guided transbronchial needle aspiration with and without rapid on-site evaluation for lung cancer genotyping. Chest 2015; 148 (6) 1430-1437
    CrossrefPubMedGoogle Scholar
  • 11 Martins RG, D'Amico TA, Loo Jr BW , et al. The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. J Natl Compr Canc Netw 2012; 10 (5) 599-613
    PubMedGoogle Scholar
  • 12 Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311 (7010) 899-909
    CrossrefPubMedGoogle Scholar
  • 13 Berghmans T, Paesmans M, Meert AP , et al. Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 2005; 49 (1) 13-23
    CrossrefPubMedGoogle Scholar
  • 14 Pignon J-P, Tribodet H, Scagliotti GV , et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26 (21) 3552-3559
    CrossrefPubMedGoogle Scholar
  • 15 Pisters KM, Evans WK, Azzoli CG , et al; Cancer Care Ontario; American Society of Clinical Oncology. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007; 25 (34) 5506-5518
    CrossrefPubMedGoogle Scholar
  • 16 Burdett S, Parmar MKB, Stewart LA, Souhami RL ; PORT Meta-analysis Trialists Group. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352 (9124) 257-263
    CrossrefPubMedGoogle Scholar
  • 17 Lally BE, Zelterman D, Colasanto JM, Haffty BG, Detterbeck FC, Wilson LD. Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database. J Clin Oncol 2006; 24 (19) 2998-3006
    CrossrefPubMedGoogle Scholar
  • 18 Douillard JY, Rosell R, De Lena M, Riggi M, Hurteloup P, Mahe MA ; Adjuvant Navelbine International Trialist Association. Impact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized Trial. Int J Radiat Oncol Biol Phys 2008; 72 (3) 695-701
    CrossrefPubMedGoogle Scholar
  • 19 Martini N, Kris MG, Flehinger BJ , et al. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg 1993; 55 (6) 1365-1373 , discussion 1373–1374
    CrossrefPubMedGoogle Scholar
  • 20 Martin J, Ginsberg RJ, Venkatraman ES , et al. Long-term results of combined-modality therapy in resectable non-small-cell lung cancer. J Clin Oncol 2002; 20 (8) 1989-1995
    CrossrefPubMedGoogle Scholar
  • 21 Shah AA, Berry MF, Tzao C , et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg 2012; 93 (6) 1807-1812
    CrossrefPubMedGoogle Scholar
  • 22 Higgins K, Chino JP, Marks LB , et al. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009; 75 (5) 1462-1467
    CrossrefPubMedGoogle Scholar
  • 23 Rusch VW, Giroux DJ, Kraut MJ , et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007; 25 (3) 313-318
    CrossrefPubMedGoogle Scholar
  • 24 Kunitoh H, Kato H, Tsuboi M , et al; Japan Clinical Oncology Group. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J Clin Oncol 2008; 26 (4) 644-649
    CrossrefPubMedGoogle Scholar
  • 25 Fischer S, Darling G, Pierre AF , et al. Induction chemoradiation therapy followed by surgical resection for non-small cell lung cancer (NSCLC) invading the thoracic inlet. Eur J Cardiothorac Surg 2008; 33 (6) 1129-1134
    CrossrefPubMedGoogle Scholar
  • 26 Pourel N, Santelmo N, Naafa N , et al. Concurrent cisplatin/etoposide plus 3D-conformal radiotherapy followed by surgery for stage IIB (superior sulcus T3N0)/III non-small cell lung cancer yields a high rate of pathological complete response. Eur J Cardiothorac Surg 2008; 33 (5) 829-836
    CrossrefPubMedGoogle Scholar
  • 27 Albain KS, Rusch VW, Crowley JJ , et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13 (8) 1880-1892
    CrossrefPubMedGoogle Scholar
  • 28 Albain KS, Swann RS, Rusch VW , et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009; 374 (9687) 379-386
    CrossrefPubMedGoogle Scholar
  • 29 van Meerbeeck JP, Kramer GWPM, Van Schil PEY , et al; European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007; 99 (6) 442-450
    CrossrefPubMedGoogle Scholar
  • 30 McElnay PJ, Choong A, Jordan E, Song F, Lim E. Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials. Thorax 2015; 70 (8) 764-768
    CrossrefPubMedGoogle Scholar
  • 31 Martin J, Ginsberg RJ, Abolhoda A , et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001; 72 (4) 1149-1154
    CrossrefPubMedGoogle Scholar
  • 32 Weder W, Collaud S, Eberhardt WEE , et al. Pneumonectomy is a valuable treatment option after neoadjuvant therapy for stage III non-small-cell lung cancer. J Thorac Cardiovasc Surg 2010; 139 (6) 1424-1430
    CrossrefPubMedGoogle Scholar
  • 33 Barnett SA, Rusch VW, Zheng J , et al. Contemporary results of surgical resection of non-small cell lung cancer after induction therapy: a review of 549 consecutive cases. J Thorac Oncol 2011; 6 (9) 1530-1536
    CrossrefPubMedGoogle Scholar
  • 34 de Cabanyes Candela S, Detterbeck FC. A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 2010; 5 (3) 389-398
    CrossrefPubMedGoogle Scholar
  • 35 De Leyn P, Stroobants S, De Wever W , et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 2006; 24 (21) 3333-3339
    CrossrefPubMedGoogle Scholar
  • 36 Galetta D, Solli P, Borri A , et al. Bronchovascular reconstruction for lung cancer: does induction chemotherapy influence the outcomes?. Ann Thorac Surg 2012; 94 (3) 907-913 , discussion 913
    CrossrefPubMedGoogle Scholar
  • 37 Morgensztern D, Campo MJ, Dahlberg SE , et al. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015; 10 (1) (Suppl. 01) S1-S63
    CrossrefPubMedGoogle Scholar
  • 38 Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. Pointed progress in second-line advanced non-small-cell lung cancer: The rapidly evolving field of checkpoint inhibition. J Clin Oncol 2016; 34 (14) 1676-1688
    CrossrefPubMedGoogle Scholar
  • 39 Xia B, Herbst RS. Immune checkpoint therapy for non-small-cell lung cancer: an update. Immunotherapy 2016; 8 (3) 279-298
    CrossrefPubMedGoogle Scholar